Dacarbazine

Generic Name: Dacarbazine

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₀N_₆O

CAS Number: 4342-03-4

Unique Ingredient Identifier: 7GR28W0FJI

Background: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Indication: For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.

Associated Conditions: Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer

Clinical Trials

Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Metformin
Drug: Melatonin
Drug: Dacarbazine

First Posted Date: 2014-07-15

Last Posted Date: 2019-11-25

Lead Sponsor: N.N. Petrov National Medical Research Center of Oncology

Target Recruit Count: 57

Registration Number: NCT02190838

Locations: 🇷🇺
N.N. Petrov Research Institute of Oncology Ambulatory Chemotherapy Department, St. Petersburg, Russian Federation
🇷🇺
N.N. Petrov Research Institute of Oncology Chemotherapy and Innovative Technologies Department, St. Petersburg, Russian Federation
🇷🇺
N.N. Petrov Research Institute of Oncology Clinical Diagnostic Department, St.Petersburg, Russian Federation

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Phase 2

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Nivolumab
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine

First Posted Date: 2014-07-04

Last Posted Date: 2023-11-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 294

Registration Number: NCT02181738

Locations: 🇺🇸
Local Institution - 0025, Boston, Massachusetts, United States
🇮🇹
Local Institution - 0019, Bologna, Italy
🇬🇧
Local Institution - 0026, Oxford, Oxfordshire, United Kingdom

and more 35 locations

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Phase 1

Conditions: Metastatic Melanoma Stage IV

Interventions: Drug: L19IL2 at RD - Ph II
Drug: L19IL2 - Ph I
Drug: DTIC

First Posted Date: 2014-03-03

Last Posted Date: 2022-04-14

Lead Sponsor: Philogen S.p.A.

Target Recruit Count: 96

Registration Number: NCT02076646

Locations: 🇩🇪
University Hospital, Tuebingen, Germany
🇮🇹
Azienda Ospedaliera Universitaria Senese, Siena, Italy

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

Phase 3

Completed

Conditions: Metastatic
Uveal Melanoma

Interventions: Drug: placebo
Drug: 75mg selumetinib
Drug: Dacarbazine

First Posted Date: 2013-11-03

Last Posted Date: 2017-01-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 152

Registration Number: NCT01974752

Locations: 🇬🇧
Research Site, Swansea, United Kingdom

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Not Applicable

Active, not recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Brentuximab vedotin (SGN-35)
Drug: Doxorubicin HCL
Drug: Vinblastine Sulfate
Drug: Dacarbazine
Radiation: Involved-Site Radiation Therapy (ISRT)
Procedure: Interim PET
Radiation: consolidation volume RT (CVRT)

First Posted Date: 2013-06-04

Last Posted Date: 2024-07-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 118

Registration Number: NCT01868451

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 7 locations

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Recurrent Uveal Melanoma
Stage IIIA Uveal Melanoma AJCC v7
Stage III Uveal Melanoma AJCC v7
Stage IIIB Uveal Melanoma AJCC v7
Stage IIIC Uveal Melanoma AJCC v7
Stage IV Uveal Melanoma AJCC v7

Interventions: Drug: Cabozantinib S-malate
Drug: Dacarbazine
Other: Laboratory Biomarker Analysis
Drug: Temozolomide

First Posted Date: 2013-04-18

Last Posted Date: 2022-08-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT01835145

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Kaiser Permanente Washington, Seattle, Washington, United States

and more 225 locations

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: AIDS-Related Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IVA Hodgkin Lymphoma
Ann Arbor Stage IIIA Hodgkin Lymphoma
Ann Arbor Stage IVB Hodgkin Lymphoma
Classic Hodgkin Lymphoma
HIV Infection
Ann Arbor Stage II Hodgkin Lymphoma
Ann Arbor Stage IIA Hodgkin Lymphoma
Ann Arbor Stage III Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Other: Pharmacological Study
Drug: Vinblastine

First Posted Date: 2013-01-18

Last Posted Date: 2024-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT01771107

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States

and more 25 locations

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Phase 3

Completed

Conditions: Metastatic or Unresectable Cutaneous Melanoma

Interventions: Drug: MEK162
Drug: Dacarbazine

First Posted Date: 2013-01-08

Last Posted Date: 2021-03-22

Lead Sponsor: Pfizer

Target Recruit Count: 402

Registration Number: NCT01763164

Locations: 🇺🇸
Harry and Jeannette Weinberg Cancer Institute @Franklin Square, Baltimore, Maryland, United States
🇺🇸
The Ohio State University James Cancer Hospital, Columbus, Ohio, United States
🇺🇸
St. Luke's Hospital - Allentown Campus, Allentown, Pennsylvania, United States

and more 188 locations

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Biological: BMS-936558 (Nivolumab)
Biological: Placebo matching BMS-936558 (Nivolumab)
Drug: Placebo matching Dacarbazine
Drug: Dacarbazine

First Posted Date: 2012-11-06

Last Posted Date: 2022-07-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 418

Registration Number: NCT01721772

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇫🇷
Local Institution - 0013, Villejuif, France
🇫🇮
Local Institution - 0035, Helsinki, Finland

and more 26 locations

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Phase 3

Completed

Conditions: Unresectable or Metastatic Melanoma

Interventions: Biological: BMS-936558
Drug: Dacarbazine
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2012-11-06

Last Posted Date: 2022-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 405

Registration Number: NCT01721746

Locations: 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸
San Francisco Oncology Associates, San Francciso, California, United States
🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States

and more 38 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy